MiniMed Group, Inc. Common Stock
NASDAQ:MMEDMedical - Care Facilities
+$0.40 today
- Market cap
- $4.78B
- Beta
- -3.63
- P/E (TTM)
- -14.2
- EPS (TTM)
- -$1.91
Volume 4.70M
Average 0.95M
MMED EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MiniMed Group, Inc. Common StockNASDAQ: MMED
EBITDA · Q1 FY2026 · quarter ended Jul 2026
EBITDA of $79M in Q1 FY2026
Q1 FY2026 EBITDA was $79M. Trailing-twelve-month EBITDA was $169M. Over 3 fiscal years it compounded at +73.9% a year.
Context
- EBITDA amounted to 6.6% of revenue in FY2025, up 2.7 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 11 analysts of $392.55M (+91.5%) for the fiscal year ending Apr 2027, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJul 2026
- $79M-34.7% QoQ
- Last fiscal yearApr 2026
- $205M+91.6% YoY
- LTMJul 2026
- $169M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | +192.2% | — |
| 1 year | +91.6% | +91.5% | -0.1 pp |
| 3-year CAGR | +73.9% | +54.5% | -19.3 pp |
| 5-year CAGR | +44.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 205M USD
- Year-over-year change
- +91.6%
- 3-year CAGR
- +73.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2026-04-24 | 205M | +91.6% |
| FY2024 | 2025-04-30 | 107M | +81.4% |
| FY2023 | 2024-04-30 | 59M | +51.3% |
| FY2022 | 2023-04-30 | 39M | — |
EBITDA vs competitors
How MMED compares with its peers on the latest reported figures
- MMED's LTM Jul 2026 EBITDA of $169M is the 4th highest of the 7 companies compared; the peer median is $296.95M.
- EBITDA amounts to 5.2% of revenue for MMED, versus a peer median of 29.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $10.27B | +9.8% | +4.1% | 27.3% | |
| LTM Jun 2026 | $1.56B | +50.0% | +33.9% | 31.4% | |
| LTM Jun 2026 | $657.4M | +61.4% | +67.2% | 21.5% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $169M | — | +73.9% | 5.2% |
| LTM Mar 2026 | -$63.5M | +7.9% | — | 57.6% | |
| LTM Mar 2026 | -$71.9M | +52.3% | — | 7.0% | |
| LTM Mar 2026 | -$80.8M | -25.3% | — | 198.5% | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding MMED) | $296.95M | +29.9% | +33.9% | 29.4% | |
Competitors are the stored peer set for MMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Apr 2023 | FY2023 Apr 2024 | FY2024 Apr 2025 | FY2025 Apr 2026 |
|---|---|---|---|---|
| Revenue | 2.25B | 2.47B | 2.72B | 3.1B |
| Cost of Revenue | 937M | 1.03B | 1.19B | 1.42B |
| Gross Profit | 1.31B | 1.44B | 1.53B | 1.68B |
| Gross Margin | 58.3% | 58.2% | 56.2% | 54.2% |
| Research & Development | 429M | 437M | 438M | 448M |
| Selling, General & Admin | 960M | 1.06B | 1.13B | 1.18B |
| Operating Expenses | 1.38B | 1.51B | 1.73B | 1.63B |
| Depreciation & Amortization | 115M | 129M | 143M | 156M |
| EBITDA | 39M | 59M | 107M | 205M |
| EBITDA Margin | 1.7% | 2.4% | 3.9% | 6.6% |
| Operating Income | (69M) | (69M) | (202M) | 49M |
| Operating Margin | -3.1% | -2.8% | -7.4% | 1.6% |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (7M) | (1M) | (1M) | (236M) |
| Income Before Tax | (76M) | (70M) | (203M) | (187M) |
| Pre-Tax Margin | -3.4% | -2.8% | -7.5% | -6.0% |
| Income Tax Expense | 16M | 38M | 48M | 128M |
| Net Income | (96M) | (112M) | (250M) | (331M) |
| Net Margin | -4.3% | -4.5% | -9.2% | -10.7% |
| EPS (Basic) | (0.34) | (0.40) | (0.89) | (1.29) |
| EPS (Diluted) | (0.34) | (0.40) | (0.89) | (1.29) |
| Weighted Avg Shares | 280.81M | 280.81M | 280.81M | 256.6M |
| Weighted Avg Shares (Diluted) | 280.81M | 280.81M | 280.81M | 256.6M |
MiniMed Group, Inc. Common Stock
NASDAQ:MMED
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.